We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-6 of 6

Learned intermediary doctrine: Eleventh Circuit upholds summary judgment in favor of manufacturer in lawsuit claiming antidepressant caused suicide
  • Locke Lord LLP
  • USA
  • May 28 2010

The 11th Circuit Court of Appeals recently relied upon the learned intermediary doctrine in affirming summary judgment in favor of Smithkline Beecham Corp. (“SBC”) in a lawsuit claiming that the antidepressant Paxil caused the decedent to commit suicide


Jury awards $141 million against Pfizer in connection with off-label use of Neurontin
  • Locke Lord LLP
  • USA
  • April 7 2010

A federal jury in Boston recently returned a verdict against Pfizer Inc. in connection with claims that Pfizer unlawfully promoted off-label uses of its anti-epilepsy drug Neurontin


Jury finds in favor of botox manufacturer in off-label use trial
  • Locke Lord LLP
  • USA
  • May 28 2010

A California jury recently returned a verdict in favor of Allergan, Inc., in a trial involving claims that Allergan’s promotion of an off-label use of its drug Botox caused the death of a pediatric patient suffering from cerebral palsy


Eight Circuit rejects FDA preemption defense raised by generic drug manufacturers
  • Locke Lord LLP
  • USA
  • February 10 2010

On November 27, 2009, the United States Court of Appeals for the Eighth Circuit held that failure to warn claims directed at generic pharmaceutical manufacturers are not preempted by federal law


Botox maker files First Amendment suit against the FDA
  • Locke Lord LLP
  • USA
  • November 3 2009

Allergan, Inc., the maker of the drug Botox, recently filed suit against the Food & Drug Administration, alleging that certain FDA regulations unconstitutionally restrict Allergan’s truthful speech regarding off-label uses of its drug